Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Ipsen
March 03, 2023

The sun sets on Exelixis’s pipeline in a product

After Cabometyx’s latest clinical setback Exelixis might have to turn to follow-on projects for future growth.

February 02, 2023

A renewed push into early bladder cancer

Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.

Article image
Vantage logo
January 11, 2023

Biopharma’s bolt-on bonanza is set to continue

With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?

Article image
Vantage logo
January 10, 2023

Amgen saves biopharma’s buyout year

December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.

Article image
Vantage logo
January 09, 2023

JP Morgan 2023 – day one sees buyers make the most of straitened times

Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.

Article image
Vantage logo
January 04, 2023

US approval tracker: December 2022

Article image
Vantage logo
December 30, 2022

Regulatory developments over the Christmas period

The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.

Article image
Vantage logo
November 30, 2022

Go or no go? Mirati heads to the FDA

TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.

Article image
Vantage logo
November 09, 2022

Takeout premiums hold up, but that’s not the whole story

Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.

Article image
Vantage logo
November 09, 2022

Merrimack triples on hopes for $225m

Article image
Vantage logo
November 09, 2022

Merrimack shows how to survive and reward investors; Clovis not so much

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up